Ascentage Pharma Group Worldwide (AAPG) This autumn 2025 Earnings Name March 26, 2026 8:00 AM EDT
Firm Contributors
Yuly Chen
Dajun Yang – Co-Founder, Chairman & CEO
Veet Misra – Chief Monetary Officer
Zhichao Si – Head of Industrial
Convention Name Contributors
Lut Ming Cheng – JPMorgan Chase & Co, Analysis Division
Biren Amin – Piper Sandler & Co., Analysis Division
Supawat Thongthip – Truist Securities, Inc., Analysis Division
Jeet Mukherjee – BTIG, LLC, Analysis Division
Matthew Biegler – Oppenheimer & Co. Inc., Analysis Division
Christopher Liu – Lucid Capital Markets, LLC, Analysis Division
Michael King – Rodman & Renshaw Analysis
Presentation
Operator
Good day, everybody, and welcome to Ascentage Pharma’s 2025 Annual Outcomes Earnings Name. [Operator Instructions] As a reminder, immediately’s name is being recorded.
Thanks for becoming a member of us. I’ll now flip the decision over to Yuly Chen, Senior Director of Investor Relations for the secure harbor assertion. Yuly, please go forward.
Yuly Chen
Thanks, operator. Please word that immediately’s dialogue will embody forward-looking statements primarily based on our present expectations and assumptions. These statements contain dangers and uncertainties and precise outcomes might differ materially. For a full dialogue of those dangers, please confer with our filings and disclosures.
On immediately’s name, I’m joined by Dr. Dajun Yang, Chairman and CEO, who will present an summary of current developments and 2025 annual efficiency. In addition to Dr. Veet Misra, CFO, who will undergo the monetary highlights. The presentation will then be adopted by a Q&A session. Throughout the Q&A session, the workforce can be joined by Dr. Yifan Zhai, Chief Medical Officer; Dr. Shaomeng Wang, Cofounder, Chief Scientific Adviser, Dr. Zhichao Si, Head of Industrial, I’ll now flip the decision over to Dr. Yang.
Dajun Yang
Co-Founder, Chairman & CEO
Thanks. Good morning. I am Dajun Yang, Chairman and CEO of the corporate. At present, I am very
